InterPAD - DETAILS

Dasatinib, 302962-49-8, Sprycel, BMS-354825, Dasatinib anhydrous, BMS 354825, Dasatinib (anhydrous), BMS354825, dasatinibum, N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE, anh. dasatinib, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide, N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, anhydrous dasatinib, Dasatinib (BMS-354825), dasatinib (anh.), N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide, BMS Dasatinib, UNII-X78UG0A0RN, X78UG0A0RN, DTXSID4040979, CHEBI:49375, NSC732517, NSC-759877, CHEMBL1421, DTXCID2020979, BMS-354825 HYDRATE, BMS 345825, NSC-732517, 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, NCGC00181129-01, BMS 35482513, BMS-354825-03, UNII-RBZ1571X5H, CHEBI:70839, C22H26ClN7O2S, DTXSID50235486, n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide, SMR002529551, CAS-302962-49-8, NSC 759877, 302962-49-8 pound not863127-77-9, Dasatinib [USAN:INN], 1N1, Kinome_3650, Dasatinib (JAN/INN), DASATINIB [INN], DASATINIB [MI], Sprycel (Bristol Meyers), DASATINIB [WHO-DD], SCHEMBL8226, Dasatinib,BMS-354825, MLS003915609, MLS004774145, MLS006010904, GTPL5678, BDBM13216, cid_3062316, Dasatinib (BMS-354825)?, DTXCID50157977, EX-A401, L01XE06, 5-Thiazolecarboxamide, monohydrate, BCPP000263, HMS2043N05, HMS3244A05, HMS3244A06, HMS3244B05, HMS3265C19, HMS3265C20, HMS3265D19, HMS3265D20, HMS3654K05, HMS3744C11, Pharmakon1600-01502275, BCP01797, Tox21_112736, MFCD11046566, NSC759877, NSC800087, s1021, AKOS015902363, Tox21_112736_1, BCP9000589, CCG-264779, CS-0100, DB01254, GS-6548, NSC-800087, SB17284, NCGC00181129-02, NCGC00181129-03, NCGC00181129-05, NCGC00181129-06, NCGC00181129-07, NCGC00181129-12, NCGC00181129-14, NCGC00181129-22, NCGC00481571-01, 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide, AC-22749, BCB03_000715, HY-10181, N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide, AM20080877, D5949, FT-0650671, NS00001968, PA-3062316, SW208076-5, D-3307, D03658, EN300-123025, AB01273956-01, AB01273956-02, AB01273956_03, AR-270/43507994, Q419940, SR-00000000554, Q-101345, SR-00000000554-5, BRD-K49328571-001-05-1, BRD-K49328571-001-07-7, Z1546610486, N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide

No.	Title	Href
1	Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal. 2011 Jul 20;6:7. doi: 10.1186/1750-2187-6-7.	`Click`
2	Combination of Phenethyl Isothiocyanate and Dasatinib Inhibits Hepatocellular Carcinoma Metastatic Potential through FAK/STAT3/Cadherin Signalling and Reduction of VEGF Secretion. Pharmaceutics. 2023 Sep 27;15(10):2390. doi: 10.3390/pharmaceutics15102390.	`Click`
3	Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis. Front Pharmacol. 2023 Oct 4;14:1264032. doi: 10.3389/fphar.2023.1264032.	`Click`

No.

Title

Href

Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal. 2011 Jul 20;6:7. doi: 10.1186/1750-2187-6-7.

Click

Combination of Phenethyl Isothiocyanate and Dasatinib Inhibits Hepatocellular Carcinoma Metastatic Potential through FAK/STAT3/Cadherin Signalling and Reduction of VEGF Secretion. Pharmaceutics. 2023 Sep 27;15(10):2390. doi: 10.3390/pharmaceutics15102390.

Click

Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis. Front Pharmacol. 2023 Oct 4;14:1264032. doi: 10.3389/fphar.2023.1264032.

Click

Name	Dasatinib
PubChem CID	3062316
Molecular Weight	488.0g/mol
Synonyms	Dasatinib, 302962-49-8, Sprycel, BMS-354825, Dasatinib anhydrous, BMS 354825, Dasatinib (anhydrous), BMS354825, dasatinibum, N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE, anh. dasatinib, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide, N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, anhydrous dasatinib, Dasatinib (BMS-354825), dasatinib (anh.), N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide, BMS Dasatinib, UNII-X78UG0A0RN, X78UG0A0RN, DTXSID4040979, CHEBI:49375, NSC732517, NSC-759877, CHEMBL1421, DTXCID2020979, BMS-354825 HYDRATE, BMS 345825, NSC-732517, 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, NCGC00181129-01, BMS 35482513, BMS-354825-03, UNII-RBZ1571X5H, CHEBI:70839, C22H26ClN7O2S, DTXSID50235486, n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide, SMR002529551, CAS-302962-49-8, NSC 759877, 302962-49-8 pound not863127-77-9, Dasatinib [USAN:INN], 1N1, Kinome_3650, Dasatinib (JAN/INN), DASATINIB [INN], DASATINIB [MI], Sprycel (Bristol Meyers), DASATINIB [WHO-DD], SCHEMBL8226, Dasatinib,BMS-354825, MLS003915609, MLS004774145, MLS006010904, GTPL5678, BDBM13216, cid_3062316, Dasatinib (BMS-354825)?, DTXCID50157977, EX-A401, L01XE06, 5-Thiazolecarboxamide, monohydrate, BCPP000263, HMS2043N05, HMS3244A05, HMS3244A06, HMS3244B05, HMS3265C19, HMS3265C20, HMS3265D19, HMS3265D20, HMS3654K05, HMS3744C11, Pharmakon1600-01502275, BCP01797, Tox21_112736, MFCD11046566, NSC759877, NSC800087, s1021, AKOS015902363, Tox21_112736_1, BCP9000589, CCG-264779, CS-0100, DB01254, GS-6548, NSC-800087, SB17284, NCGC00181129-02, NCGC00181129-03, NCGC00181129-05, NCGC00181129-06, NCGC00181129-07, NCGC00181129-12, NCGC00181129-14, NCGC00181129-22, NCGC00481571-01, 2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide, AC-22749, BCB03_000715, HY-10181, N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide, AM20080877, D5949, FT-0650671, NS00001968, PA-3062316, SW208076-5, D-3307, D03658, EN300-123025, AB01273956-01, AB01273956-02, AB01273956_03, AR-270/43507994, Q419940, SR-00000000554, Q-101345, SR-00000000554-5, BRD-K49328571-001-05-1, BRD-K49328571-001-07-7, Z1546610486, N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide
Drug Type	Small molecule
Formula	C₂₂H₂₆ClN₇O₂S
SMILES	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
InChI	1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
InChIKey	ZBNZXTGUTAYRHI-UHFFFAOYSA-N
CAS Number	302962-49-8
ChEMBL ID	CHEMBL1421
ChEBI ID	CHEBI:49375
TTD ID	D0E6XR
Drug Bank ID	DB01254
KEGG ID	D03658
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Phenethyl isothiocyanate, Dasatinib
Partner Name	Phenethyl isothiocyanate
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Angiogenesis
Gene Regulation	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	CDH2	hsa1000
	Down-regulation	Phosphorylation	PTK2	hsa5747
	Down-regulation	Phosphorylation	STAT3	hsa6774
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
In Vitro Model	Hepa 1-6	Hepatocellular carcinoma of the mouse	Mus musculus (Mouse)	CVCL_0327
Result	The inhibition of FAK/STAT3 signalling led to increased E-cadherin expression and reduced VEGF secretion, reducing HCC metastatic potential. Therefore, a combination of PEITC and dasatinib could be a potential therapeutic strategy for the treatment of HCC.

Pair Name	Phenethyl isothiocyanate, Dasatinib
Partner Name	Phenethyl isothiocyanate
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Up-regulation	Phosphorylation	AIFM1	hsa9131
	Down-regulation	Expression	CCNB1	hsa891
	Down-regulation	Expression	CDK1	hsa983
	Down-regulation	Expression	KEAP1	hsa9817
	Up-regulation	Cleavage	PGAM5	hsa192111
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
In Vitro Model	Hepa 1-6	Hepatocellular carcinoma of the mouse	Mus musculus (Mouse)	CVCL_0327
In Vivo Model	Hepa 1-6 cells (5×10⁶ cells in 100 µL MEM) were injected subcutaneously in the right flank of 40 9–10-week-old female C57BL6 mice.
Result	PEITC showed to enhance dasatinib action in treating HCC with increased production of ROS that induced cell cycle arrest followed by mitotic catastrophe, and to induce oxeiptosis. These results highlight the role that ITCs may have in cancer therapy as a complement of clinically approved chemotherapeutic drugs

Pair Name	Curcumin, Dasatinib
Partner Name	Curcumin
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Cell invasion and colonosphere formation
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
In Vitro Model	HT-29	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0320
Result	Our data suggest that the combination therapy of dasatinib and curcumin may be a therapeutic strategy for re-emergence of chemo-resistant colon cancer by targeting CSC sub-population.